NZ737561A - Oral composition of celecoxib for treatment of pain - Google Patents
Oral composition of celecoxib for treatment of painInfo
- Publication number
- NZ737561A NZ737561A NZ737561A NZ73756116A NZ737561A NZ 737561 A NZ737561 A NZ 737561A NZ 737561 A NZ737561 A NZ 737561A NZ 73756116 A NZ73756116 A NZ 73756116A NZ 737561 A NZ737561 A NZ 737561A
- Authority
- NZ
- New Zealand
- Prior art keywords
- celecoxib
- pain
- composition
- treatment
- oral
- Prior art date
Links
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 title abstract 7
- 229960000590 celecoxib Drugs 0.000 title abstract 7
- 208000002193 Pain Diseases 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 3
- 206010002556 Ankylosing Spondylitis Diseases 0.000 abstract 1
- 208000000094 Chronic Pain Diseases 0.000 abstract 1
- 206010013935 Dysmenorrhoea Diseases 0.000 abstract 1
- 201000006107 Familial adenomatous polyposis Diseases 0.000 abstract 1
- 208000003456 Juvenile Arthritis Diseases 0.000 abstract 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 abstract 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 abstract 1
- 208000005298 acute pain Diseases 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 208000019069 chronic childhood arthritis Diseases 0.000 abstract 1
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 abstract 1
- 230000003111 delayed effect Effects 0.000 abstract 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 abstract 1
- 239000008203 oral pharmaceutical composition Substances 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN2682CH2015 | 2015-05-28 | ||
| IN6614CH2015 | 2015-12-10 | ||
| PCT/US2016/034844 WO2016191744A1 (en) | 2015-05-28 | 2016-05-27 | Oral composition of celecoxib for treatment of pain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ737561A true NZ737561A (en) | 2019-08-30 |
Family
ID=56137539
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ737561A NZ737561A (en) | 2015-05-28 | 2016-05-27 | Oral composition of celecoxib for treatment of pain |
Country Status (12)
| Country | Link |
|---|---|
| US (7) | US9572819B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3302429A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6605047B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR101994129B1 (cg-RX-API-DMAC7.html) |
| CN (3) | CN107847437B (cg-RX-API-DMAC7.html) |
| AU (2) | AU2016267685A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2987272C (cg-RX-API-DMAC7.html) |
| EA (1) | EA038013B1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX384044B (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ737561A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2708254C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016191744A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107847437B (zh) * | 2015-05-28 | 2024-03-26 | 瑞迪博士实验室有限公司 | 用于治疗疼痛的塞来昔布口服组合物 |
| CN119055585A (zh) | 2016-05-27 | 2024-12-03 | 雷迪博士实验室有限公司 | 用于治疗疼痛的塞来昔布口服组合物 |
| US11770123B2 (en) | 2018-01-05 | 2023-09-26 | Darfon Electronics Corp. | Optical keyswitch comprising a keycap having a light transmission area and a keycap projection area projected on a circuit board |
| US11108393B2 (en) | 2018-01-05 | 2021-08-31 | Darfon Electronics Corp. | Optical keyswitch triggered by support mechanism having at least one rotatable frame enable a protrusion to move along with a key cap |
| CA3144079A1 (en) | 2020-12-28 | 2022-06-28 | Biodelivery Sciences International, Inc. | Methods of treating pain |
| US11735379B2 (en) | 2021-04-07 | 2023-08-22 | Darfon Electronics Corp. | Keyswitch assembly |
| US11721500B2 (en) | 2021-04-07 | 2023-08-08 | Darfon Electronics Corp. | Keyswitch assembly and support mechanism thereof |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992018106A1 (fr) | 1991-04-16 | 1992-10-29 | Nippon Shinyaku Co., Ltd. | Procede de production d'une dispersion solide |
| DE69422306D1 (de) | 1993-11-30 | 2000-01-27 | Searle & Co | Substituierte pyrazolyl-benzolsulfonamide zur behandlung von entzündungen |
| US5466823A (en) | 1993-11-30 | 1995-11-14 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides |
| GB9405304D0 (en) | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
| US5993858A (en) | 1996-06-14 | 1999-11-30 | Port Systems L.L.C. | Method and formulation for increasing the bioavailability of poorly water-soluble drugs |
| US6531139B1 (en) | 1997-07-29 | 2003-03-11 | Pharmacia & Upjohn Company | Self-emulsifying formulation for lipophilic compounds |
| EP2127642A3 (en) | 1998-08-13 | 2010-02-24 | Cima Labs, Inc. | Microemulsions as solid dosage forms for oral administration |
| SA99191255B1 (ar) * | 1998-11-30 | 2006-11-25 | جي دي سيرل اند كو | مركبات سيليكوكسيب celecoxib |
| JP2002531515A (ja) | 1998-12-11 | 2002-09-24 | ファーマソリューションズ・インコーポレイテッド | 水に難溶性の薬剤のための自己乳化組成物 |
| US6267985B1 (en) * | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
| US7374779B2 (en) | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| US6761903B2 (en) | 1999-06-30 | 2004-07-13 | Lipocine, Inc. | Clear oil-containing pharmaceutical compositions containing a therapeutic agent |
| US6383471B1 (en) * | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
| US6057289A (en) | 1999-04-30 | 2000-05-02 | Pharmasolutions, Inc. | Pharmaceutical composition comprising cyclosporin in association with a carrier in a self-emulsifying drug delivery system |
| US6720001B2 (en) | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
| CZ20013162A3 (cs) * | 1999-12-08 | 2002-06-12 | Pharmacia Corporation | Prostředky obsahující inhibitor cyklooxygenasy-2 mající rychlý nástup terapeutického účinku |
| NZ513964A (en) * | 1999-12-08 | 2004-01-30 | Pharmacia Corp | Solid-state form of celecoxib having enhanced bioavailability |
| CA2406226A1 (en) | 2000-04-18 | 2001-10-25 | Pharmacia Corporation | Rapid-onset formulation of a selective cyclooxigenase-2 |
| US20080009467A1 (en) * | 2000-05-01 | 2008-01-10 | Accera, Inc. | Combinations of medium chain triglycerides and therapeutic agents for the treatment and prevention of alzheimers disease and other diseases resulting from reduced neuronal metabolism |
| AR035642A1 (es) * | 2000-05-26 | 2004-06-23 | Pharmacia Corp | Uso de una composicion de celecoxib para el alivio rapido del dolor |
| WO2002036110A2 (en) | 2000-10-31 | 2002-05-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Oral self-emulsifying formulations of pyranone protease inhibitors |
| CZ20033341A3 (cs) | 2001-06-21 | 2004-10-13 | Pfizeráproductsáinc | Samoemulgující se kompozice inhibitorů přenosového proteinu cholesterylesteru |
| US20030073609A1 (en) * | 2001-06-29 | 2003-04-17 | Pinkerton Thomas C. | Enhanced pharmacokinetic profile of intradermally delivered substances |
| WO2004000284A1 (en) | 2002-06-21 | 2003-12-31 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions with improved dissolution |
| IL164163A0 (en) | 2002-04-09 | 2005-12-18 | Pharmacia Corp | Process for preparing a finely self-emulsifiable pharmaceutical composition |
| US6689382B2 (en) * | 2002-05-15 | 2004-02-10 | Procaps S.A. | Soft shell gelatin capsules containing non-steroidal anti-inflammatories |
| AU2003295846A1 (en) * | 2002-11-26 | 2004-06-18 | Transform Pharmaceuticals, Inc. | Pharmaceutical formulations of celcoxib |
| EP1706098A4 (en) * | 2003-11-26 | 2012-08-15 | Supernus Pharmaceuticals Inc | MICELLAR SYSTEMS SUITABLE FOR THE DELIVERY OF LIPOPHILIC OR HYDROPHOBIC COMPOUNDS |
| CA2647533A1 (en) | 2006-03-28 | 2007-10-04 | Javelin Pharmaceuticals, Inc. | Formulations of low dose non-steroidal anti-inflammatory drugs and beta-cyclodextrin |
| EP1961412A1 (en) | 2006-12-27 | 2008-08-27 | LEK Pharmaceuticals D.D. | Self-microemulsifying drug delivery systems |
| WO2008115572A1 (en) | 2007-03-21 | 2008-09-25 | Theraquest Biosciences, Inc. | Methods and compositions of nsaids |
| WO2009063367A1 (en) * | 2007-11-15 | 2009-05-22 | Pfizer Products Inc. | Dosage forms comprising celecoxib providing both rapid and sustained pain relief |
| WO2010150144A2 (en) * | 2009-06-25 | 2010-12-29 | Wockhardt Research Centre | Low dose pharmaceutical compositions of celecoxib |
| EP2311446A1 (en) * | 2009-10-16 | 2011-04-20 | Laboratorios Del. Dr. Esteve, S.A. | Compositions comprising Tramadol and Celecoxib in the treatment of pain |
| EP2340819A1 (en) * | 2009-12-23 | 2011-07-06 | Laboratorios Del. Dr. Esteve, S.A. | Compositions comprising venlafaxine and celecoxib in the treatment of pain |
| WO2012037328A2 (en) * | 2010-09-17 | 2012-03-22 | Maine Natural Health, Inc. | Compositions containing omega-3 oil with an anti-inflammatory agent and uses thereof |
| KR101413846B1 (ko) * | 2012-04-12 | 2014-06-30 | 주식회사 종근당 | ４－［５－（４－메칠페닐）－３－（트리플루오로메칠）피라졸－１－일］벤젠술폰아미드 화합물 함유 액상 조성물 |
| KR101455901B1 (ko) * | 2012-05-04 | 2014-11-03 | 성균관대학교산학협력단 | 세레콕시브 및 폴록사머를 포함하는 공융 혼합물 |
| KR20140100170A (ko) * | 2013-02-05 | 2014-08-14 | 에스케이케미칼주식회사 | 셀레콕시브 경구투여용 조성물 |
| MX349193B (es) | 2013-08-27 | 2017-07-18 | Alparis Sa De Cv | Capsula con contenido liquido con un antiinflamatorio. |
| EP3104840B8 (en) * | 2014-02-11 | 2019-07-10 | Latitude Pharmaceuticals Inc. | Parenteral compositions of celecoxib |
| US20150342893A1 (en) * | 2014-05-29 | 2015-12-03 | Sigmoid Pharma Limited | Celecoxib formulations useful for treating colorectal cancer |
| CN107847437B (zh) * | 2015-05-28 | 2024-03-26 | 瑞迪博士实验室有限公司 | 用于治疗疼痛的塞来昔布口服组合物 |
| AU2016270504A1 (en) * | 2015-05-29 | 2017-12-14 | Codadose Incorporated | Liquid formulations of celecoxib for oral administration |
-
2016
- 2016-05-27 CN CN201680031177.5A patent/CN107847437B/zh active Active
- 2016-05-27 AU AU2016267685A patent/AU2016267685A1/en not_active Abandoned
- 2016-05-27 NZ NZ737561A patent/NZ737561A/en not_active IP Right Cessation
- 2016-05-27 EA EA201792530A patent/EA038013B1/ru unknown
- 2016-05-27 JP JP2017561947A patent/JP6605047B2/ja active Active
- 2016-05-27 US US15/167,922 patent/US9572819B2/en active Active
- 2016-05-27 KR KR1020177035928A patent/KR101994129B1/ko active Active
- 2016-05-27 EP EP16730581.2A patent/EP3302429A1/en active Pending
- 2016-05-27 CA CA2987272A patent/CA2987272C/en active Active
- 2016-05-27 CN CN202311387716.7A patent/CN117547528A/zh active Pending
- 2016-05-27 CN CN202111630363.XA patent/CN114209707A/zh active Pending
- 2016-05-27 RU RU2017144574A patent/RU2708254C2/ru active
- 2016-05-27 MX MX2017015238A patent/MX384044B/es unknown
- 2016-05-27 WO PCT/US2016/034844 patent/WO2016191744A1/en not_active Ceased
- 2016-12-09 US US15/374,951 patent/US9795620B2/en active Active
-
2017
- 2017-09-22 US US15/712,415 patent/US9949990B2/en active Active - Reinstated
-
2018
- 2018-03-15 US US15/922,353 patent/US10799517B2/en active Active
- 2018-03-15 US US15/922,170 patent/US10376527B2/en active Active
-
2019
- 2019-03-29 US US16/369,981 patent/US20190224219A1/en not_active Abandoned
- 2019-05-31 AU AU2019203815A patent/AU2019203815A1/en not_active Abandoned
-
2021
- 2021-09-10 US US17/471,858 patent/US20220241298A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ737561A (en) | Oral composition of celecoxib for treatment of pain | |
| PH12015502691A1 (en) | Use of high dose pridopidine for treating huntington's disease | |
| AU2012284627A8 (en) | Method for manufacturing a pharmaceutical composition in the form of extended-release tablets containing Pirfenidone and use thereof in the regression of chronic renal insufficiency, breast capsular contracture and hepatic fibrosis in humans | |
| RU2019134558A (ru) | Композиции и способы лечения анемии | |
| BR112018012870A2 (pt) | métodos e composições para o tratamento de transtornos relacionados à crise | |
| JP2018507243A5 (cg-RX-API-DMAC7.html) | ||
| ZA202000028B (en) | Use of vibegron to treat overactive bladder | |
| PH12020550815A1 (en) | Delayed release deferiprone tablets and methods of using the same | |
| MX380070B (es) | Una composición farmacéutica que comprende amlodipino, valsartán y rosuvastatina. | |
| RU2018146504A (ru) | Лечение внутрипеченочных холестатических заболеваний | |
| JP2016505050A5 (cg-RX-API-DMAC7.html) | ||
| MX2015009546A (es) | Dosificacion aumentada de efavirenz para el tratamiento de cancer. | |
| WO2019055942A4 (en) | Methods and compositions to inhibit tolerance to opioids | |
| EA202193065A1 (ru) | Фармацевтическая композиция, содержащая акситиниб | |
| MX2013003523A (es) | Composicion farmaceutica de dosis baja. | |
| RU2016137926A (ru) | Композиции грапипранта и способы их применения | |
| HRP20161796T1 (hr) | Farmaceutski pripravak za primjenu u tretmanu ili prevenciji deficijencije vitamina i minerala kod pacijenata podvrgnutih operaciji želučane premosnice | |
| ZA202405485B (en) | Solid oral dosage forms of rabeprazole | |
| SG10201803996WA (en) | Anti-tuberculosis stable pharmaceutical composition in a form of a dispersible tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation | |
| JP2017515858A5 (cg-RX-API-DMAC7.html) | ||
| MX2022000663A (es) | Formulaciones farmaceuticas que contienen gaboxadol para tratamiento terapeutico. | |
| EA202090416A1 (ru) | Способы лечения симптомов гастропареза с использованием велусетрага | |
| MX2017009660A (es) | Composicion farmaceutica con un rango de relacion entre el clorhidrato de tramadol y el etoricoxib para su administracion para el tratamiento del dolor. | |
| EA201692107A1 (ru) | Схема лечения тиакумициновым соединением | |
| HK1225969A1 (zh) | 利用低剂量的拉喹莫德治疗克隆氏病 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 MAY 2021 BY COMPUTER PACKAGES INC Effective date: 20200519 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 MAY 2022 BY COMPUTER PACKAGES INC Effective date: 20210530 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 MAY 2023 BY COMPUTER PACKAGES INC Effective date: 20220430 |
|
| LAPS | Patent lapsed |